Lithium Orotate for Alzheimer’s Prevention
Exploring Strategies
for Optimum Cognitive Health
Alzheimer’s Disease (AD) is a
progressive neurodegenerative disorder that impacts millions of people
worldwide, leading to memory loss, cognitive decline, and diminished quality of
life. According to neurologist Dr. Daniel Press, researchers are focusing on amyloid
removal therapies, as AD is a massive health problem. In the United States, there
are 61.2 million older adults and six million have been diagnosed with AD,
costing $18 billion annually. That number is increasing because there are more
people living beyond the age of eighty. As researchers continue to search for
effective prevention strategies, lithium orotate has gained attention
for its potential to support brain health. Separately, emerging research
suggests that reduced lithium orotate availability in the brain may be
associated with mild cognitive impairment (MCI) and Alzheimer’s Disease, though
whether this relationship is causal in humans is not yet established.
Lithium Orotate: A
Trace Mineral with Neuroprotective Properties
What is it? Lithium orotate is thought
to enhance lithium’s absorption in the body. Unlike the prescription form, lithium
carbonate, used for mood disorders, bipolar, and psychiatric care, lithium
orotate is available as a dietary supplement at much lower doses. Recent rodent
studies suggest that lithium orotate may promote neurogenesis, protect neurons
from damage, and reduce the buildup of amyloid plaques—hallmarks of Alzheimer’s
Disease. Although the research is still in its early stages, some findings
indicate that low-dose lithium orotate supplementation, 5 mg to 10 mg daily,
may help preserve cognitive function and slow disease progression by clearing amyloid
plaques and accumulated tau protein in the brain. It is extremely safe and
there is no toxicity when taken at these low doses.
What the Evidence Suggests
and What it does Not
The idea that “lithium loss ignites
Alzheimer’s disease” comes from recent research proposing that naturally
occurring lithium in the brain may help support normal brain aging—and that a
drop in brain lithium availability could be an early event in Alzheimer’s Disease.
In this model, lithium becomes less available partly because it is sequestered
(or bound) by amyloid plaques, potentially disrupting protective signaling
pathways.
In a 2025 study published in Nature,
researchers reported that lithium was the only one of dozens of measured trace
metals that was significantly reduced in the prefrontal cortex in people with
mild cognitive impairment (MCI) and AD, and that lithium appeared concentrated
within amyloid plaques—consistent with the hypothesis that plaques can “trap”
lithium and reduce its bioavailability in surrounding brain tissue.
In mouse models, reducing dietary
lithium (lowering brain lithium) was associated with increased amyloid-β
deposition and tau accumulation, pro-inflammatory activation, synaptic/axonal
changes, and faster cognitive decline. However, these findings do NOT prove
that low lithium causes Alzheimer’s in humans, nor that over-the-counter
lithium orotate supplements prevent dementia. Clinical trials of low-dose
lithium orotate in MCI and Alzheimer’s remain limited; a 2026 pilot randomized
trial in MCI found the intervention feasible and generally well tolerated, but
none of its prespecified primary outcomes met the study’s significance
threshold.
References
and Further Reading:
Aron,
L., Ngian, Z.K., Qiu, C. et al. Lithium deficiency and the onset of
Alzheimer’s disease. Nature 645, 712–721 (2025). https://doi.org/10.1038/s41586-025-09335-x
Beach,
S.R. Lithium orotate: Breakthrough treatment for Alzheimer’s Disease?
Psychopharmacology Institute. (Accessed 2026).
Dutchen,
S. (2025, August 12). Could lithium explain and treat Alzheimer’s Disease? https://hms.harvard.edu/news/could-lithium-explain-treat-alzheimers-disease
U.S.
Census Bureau. QuickFacts: United States. “Persons 65 years and over, percent”:
18.0% (table PST045224; accessed 2026).
No comments:
Post a Comment